SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Silvia Hernández-LlodràLaura SegalésAinara SafontNuria JuanpereMarta LorenzoLluís FumadóAlejo Rodríguez-VidaLluís CecchiniJoaquim BellmuntJosep Lloreta-TrullPublished in: The Prostate (2019)
In conclusion, SPOP and FOXA1 mutations may have prognostic value in ERG wt tumors. Interestingly, in absence of SPOP mutations, downregulation of this gene is a feature of many ERG-rearranged prostate tumors.